U.S. HLA Typing for Transplant Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

HLA Typing for Transplant Market Size

• The U.S. HLA Typing for Transplant market size was valued at USD 1.41 billion in 2025 and is expected to reach USD 3.13 billion by 2033, at a CAGR of 10.50% during the forecast period
• The market growth is largely fueled by the increasing prevalence of organ and stem cell transplants worldwide, coupled with the critical need for accurate HLA typing to ensure donor-recipient compatibility and reduce the risk of transplant rejection. Advances in molecular diagnostics, automation, and high-throughput sequencing technologies are further enhancing the efficiency and precision of HLA typing, driving market adoption
• Furthermore, rising awareness among healthcare providers and patients regarding the importance of immunogenetic matching, along with increasing investments in transplant programs and precision medicine initiatives, is establishing HLA Typing for Transplant solutions as an essential tool in modern transplant management. These converging factors are accelerating the uptake of HLA typing solutions, thereby significantly boosting the industry’s growth

HLA Typing for Transplant Market Analysis

• HLA Typing for Transplant solutions, offering precise donor-recipient compatibility testing for organ and stem cell transplants, are increasingly vital components of modern transplant management systems in both hospitals and specialized diagnostic laboratories due to their enhanced accuracy, faster turnaround times, and integration with automated molecular diagnostic platforms
• The escalating demand for HLA Typing for Transplant is primarily fueled by the growing number of organ and stem cell transplants, rising awareness regarding immunogenetic matching, and increasing adoption of advanced molecular and high-throughput sequencing technologies
• The U.S. dominated the HLA Typing for Transplant market with the largest revenue share in 2025, driven by advanced healthcare infrastructure, high number of organ and stem cell transplants, strong adoption of molecular diagnostics, and the presence of leading HLA typing solution providers
• The molecular assay technologies segment dominated the market with a revenue share of around 55.6% in 2025, driven by the high precision, sensitivity, and reliability of DNA-based testing methods such as PCR, NGS, and SSO

Report Scope and HLA Typing for Transplant Market Segmentation  

HLA Typing for Transplant Market Trends

Growing Adoption of Advanced Molecular and Genotyping Techniques

• A significant trend in the HLA Typing for Transplant market is the rising use of high-resolution molecular typing techniques, including next-generation sequencing (NGS) and PCR-based methods, which provide accurate and detailed HLA profiles for both donors and recipients
  • For instance, the Mayo Clinic in the U.S. implemented NGS-based HLA typing for bone marrow transplants, reducing ambiguities in donor-recipient matching and improving transplant success rates. Similarly, European transplant centers have adopted multiplex PCR platforms for faster, reliable typing in urgent cases
• The trend toward automation and high-throughput processing is enabling laboratories to handle larger donor pools and reduce manual errors, accelerating the overall transplant workflow
• Integration of bioinformatics and AI-driven data analysis allows for precise interpretation of complex HLA allele variations, facilitating personalized transplant planning
• Increasing collaboration among global donor registries and laboratories is driving standardization of HLA typing protocols, improving compatibility matching for international transplants

HLA Typing for Transplant Market Dynamics

Driver

Increasing Number of Organ and Stem Cell Transplants

• Rising prevalence of chronic diseases, hematologic disorders, and organ failures is driving demand for accurate HLA typing, as precise matching is critical to reduce graft rejection and post-transplant complications
  • For instance, in 2024, the National Marrow Donor Program (NMDP) in the U.S. recorded a surge in bone marrow transplants among leukemia patients, leading hospitals to adopt rapid, high-resolution HLA typing platforms to ensure timely donor-recipient matches. Similarly, Japan’s leading cardiac and hematology centers have integrated automated HLA typing workflows to meet growing transplant demand
• The expansion of national and regional donor registries is increasing the need for standardized, high-quality HLA typing services to manage large volumes of donor-recipient matches efficiently
• Technological innovations such as microarray-based HLA typing and fully automated sequencing are enhancing laboratory efficiency, reducing turnaround times, and supporting high-volume transplant programs
• Rising awareness among clinicians and patients about the importance of HLA compatibility is increasing adoption rates of advanced typing services, particularly in specialized hospitals and transplant centers

Restraint/Challenge

High Cost of Advanced HLA Typing and Limited Accessibility

• The high cost of advanced HLA typing platforms such as next-generation sequencing (NGS) and automated PCR systems remains a significant barrier, particularly for smaller hospitals, diagnostic centers, and healthcare facilities in developing regions. These high upfront costs can deter adoption despite the clinical benefits of high-resolution typing
  • For instance, in India, many regional hospitals still rely on conventional serological HLA typing due to budget constraints, which may lead to lower match accuracy and a higher risk of graft rejection compared to high-resolution molecular methods
• The requirement for skilled laboratory personnel poses a challenge, as operating advanced HLA platforms requires specialized training in molecular biology, sequencing, and bioinformatics. Many regions face a shortage of trained technicians, leading to delays in testing and potential errors in results
• Infrastructure limitations such as inadequate laboratory space, outdated equipment, insufficient quality control protocols, and limited maintenance support can further impede efficient HLA typing operations. These constraints are particularly evident in community hospitals and smaller diagnostic labs
• Regulatory and compliance challenges across different countries add complexity to market expansion. Laboratories must adhere to stringent quality and accreditation standards, such as ISO 15189 and CAP (College of American Pathologists) certification, which can be resource-intensive and time-consuming to implement
• Turnaround time for advanced typing tests can be a limiting factor, especially in urgent transplant cases where rapid donor-recipient matching is critical. While high-resolution typing improves accuracy, longer processing times in under-equipped labs may delay transplantation procedures
• Data management and interoperability issues can arise when integrating HLA typing results with hospital information systems and donor registries. Lack of standardized formats and secure data-sharing protocols may hinder efficient coordination between transplant centers and donor databases
• Limited insurance coverage and reimbursement in certain regions can restrict patient access to advanced HLA typing services. Patients in countries with lower healthcare funding may not be able to afford high-resolution typing, even when it is clinically recommended

HLA Typing for Transplant Market Scope

The HLA Typing for Transplant market is segmented on the basis of product, application, technology, and end user.

• By Product

On the basis of product, the HLA Typing for Transplant market is segmented into reagents and consumables, instruments, and software & services. The reagents and consumables segment dominated the largest market revenue share of around 47.5% in 2025, driven by the recurring requirement of these products in HLA testing procedures. Reagents such as antibodies, primers, and probes are essential for accurate HLA typing and compatibility testing between donors and recipients. Hospitals, diagnostic laboratories, and research centers rely heavily on high-quality consumables to ensure precise results and reduce the risk of transplant rejection. The growing number of organ transplant procedures worldwide has significantly increased the demand for reagents and consumables. In addition, technological advancements in molecular assay kits and high-throughput testing methods are enhancing reagent efficiency and accuracy. The adoption of automated platforms in laboratories further supports reagent consumption, as these systems require continuous supplies of specialized consumables. The increasing awareness of transplant compatibility testing and government initiatives to improve organ donation programs also boost segment growth. Reagents and consumables are widely used across diagnostic, research, and clinical applications, maintaining their dominant market position. Furthermore, the recurring expenditure on these products ensures steady revenue generation for manufacturers.

The instruments and software & services segment is expected to witness the fastest CAGR of 8.2% from 2026 to 2033, driven by the rising adoption of advanced HLA typing platforms and bioinformatics tools. Instruments such as PCR machines, sequencers, and automated analyzers are increasingly used in modern laboratories to enhance testing speed and accuracy. Software solutions support data management, interpretation, and reporting, improving overall laboratory efficiency. Research and clinical laboratories are adopting integrated systems combining hardware and software for high-throughput HLA typing. Furthermore, growing investments in molecular diagnostics and bioinformatics are driving demand for these solutions. The rising number of complex transplant procedures requiring precise donor-recipient matching is also contributing to segment growth. Academic institutions and research labs are increasingly utilizing software and services for translational research in transplantation immunology. In addition, cloud-based services and AI-assisted data analysis are enhancing the adoption of software solutions in HLA typing workflows. As hospitals and diagnostic centers upgrade to modern platforms, this segment is expected to grow rapidly over the forecast period.

• By Application

On the basis of application, the HLA Typing for Transplant market is segmented into diagnostic applications, donor-recipient cross-matching, infectious disease testing, cancer diagnosis and prevention, transfusion therapy, other diagnostic applications, and research applications. The donor-recipient cross-matching segment held the largest market revenue share of approximately 39.2% in 2025, primarily due to its critical role in organ transplantation. Accurate cross-matching ensures compatibility between donors and recipients, minimizing the risk of transplant rejection and improving post-transplant outcomes. The increasing number of organ transplant procedures worldwide is driving the demand for HLA typing in cross-matching applications. Hospitals and specialized transplant centers rely on molecular and non-molecular HLA typing technologies to evaluate donor-recipient compatibility efficiently. Technological advancements in high-resolution typing methods have improved accuracy, further supporting segment growth. Government initiatives promoting organ donation programs and awareness about transplantation safety also boost adoption. In addition, the rising prevalence of chronic kidney disease, liver failure, and other organ disorders is increasing the demand for transplant procedures. The segment benefits from recurring testing needs for pre- and post-transplant patient monitoring. As transplantation procedures continue to grow globally, donor-recipient cross-matching remains the leading application in the market.

The cancer diagnosis and prevention segment is expected to witness the fastest CAGR of 8.5% from 2026 to 2033, driven by the expanding use of HLA typing in immunotherapy and personalized cancer treatment. HLA typing helps identify patients eligible for targeted therapies and immunotherapeutic interventions by understanding individual immune profiles. Rising cancer incidence globally and increasing adoption of precision medicine are driving demand for HLA-based diagnostics. Academic and research institutions are increasingly conducting studies linking HLA types to cancer susceptibility, which further supports segment growth. In addition, technological advancements in molecular assays facilitate rapid and accurate HLA typing for oncology applications. As awareness of personalized treatment and immunogenetics grows, the adoption of HLA typing in cancer diagnosis and prevention is expected to increase significantly over the forecast period.

• By Technology

On the basis of technology, the HLA Typing for Transplant market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment dominated the market with a revenue share of around 55.6% in 2025, driven by the high precision, sensitivity, and reliability of DNA-based testing methods such as PCR, NGS, and SSO. Molecular assays provide high-resolution typing, enabling accurate donor-recipient matching and improving transplant success rates. The increasing demand for automated and high-throughput testing systems is further supporting growth. Hospitals, transplant centers, and diagnostic laboratories prefer molecular technologies due to their reproducibility and ability to detect rare HLA variants. Technological advancements and the availability of comprehensive molecular kits are boosting adoption globally. In addition, the rising prevalence of organ transplantation and the need for immunogenetic research contribute to segment dominance.

The non-molecular assay technologies segment is expected to witness the fastest CAGR of 7.8% from 2026 to 2033, driven by the continued use of serological and flow cytometry-based methods in certain clinical settings. These methods are used for rapid screening, preliminary typing, and cases where molecular assays may not be feasible. Non-molecular methods remain cost-effective and are widely deployed in emerging economies where advanced molecular platforms are less accessible. Increasing integration with automated laboratory workflows and hybrid approaches is also supporting growth.

• By End User

On the basis of end user, the HLA Typing for Transplant market is segmented into commercial service providers, hospitals and surgical centres, research laboratories, and academic institutes. The hospitals and surgical centres segment dominated the market with the largest revenue share of approximately 43.7% in 2025, driven by their role in performing organ transplantation and related diagnostic testing. Hospitals require reliable HLA typing solutions for donor-recipient matching and post-transplant monitoring. Advanced laboratories within surgical centers and hospitals are equipped with high-throughput instruments and consumables to support frequent testing. Increasing organ transplant procedures globally and improvements in hospital infrastructure contribute to segment growth. In addition, government support for transplantation programs and healthcare awareness campaigns promote the adoption of HLA typing in clinical settings. Hospitals and surgical centers remain the preferred end users for integrated testing solutions, including molecular assays and software tools.

The research laboratories and academic institutes segment is expected to witness the fastest CAGR of 8.3% from 2026 to 2033, driven by rising research in immunogenetics, transplantation biology, and precision medicine. These institutions conduct studies on HLA-disease associations, donor-recipient compatibility, and immunotherapy development. Growing funding for translational research and biotechnology innovation supports the demand for advanced HLA typing technologies. Integration of bioinformatics and AI-assisted data analysis in research workflows further accelerates adoption. As interest in personalized medicine, immunogenetics, and organ transplantation research increases, this segment is expected to expand rapidly over the forecast period.

HLA Typing for Transplant Market Share

The HLA Typing for Transplant industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific (U.S.)
• Illumina, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• B.D. (U.S.)
• PerkinElmer, Inc. (U.S.)
• Hologic, Inc. (U.S.)
• CareDx, Inc. (U.S.)
• One Lambda, Inc. (U.S.)
• Abbott Laboratories (U.S.)
• GenDx (Netherlands)
• Immucor, Inc. (U.S.)
• Oxford Immunotec Ltd. (U.K.)
• Fujirebio Inc. (Japan)
• Luminex Corporation (U.S.)
• GenScript Biotech Corporation (China)
• Takara Bio Inc. (Japan)
• BGI Group (China)
• Roche Diagnostics (Switzerland)
• Eurofins Scientific (Luxembourg)

Latest Developments in U.S. HLA Typing for Transplant Market

• In April 2021, CareDx, Inc. launched a fully functional next‑generation sequencing (NGS) HLA typing service lab in Stockholm, Sweden, offering high‑resolution HLA typing using the AlloSeq Tx17 test to support research, vaccine and drug development as well as transplant compatibility studies. This expansion marked CareDx’s first HLA testing service outside the United States and broadened global access to advanced typing services
• In March 2024, Illumina, Inc. and GenDx announced a strategic partnership to co‑develop next‑generation sequencing (NGS)‑based HLA typing software combining GenDx’s NGSengine with Illumina’s sequencing platforms, aimed at enhancing high‑resolution HLA typing workflows for clinical and research laboratories in the US and Europe
• In May 2024, Thermo Fisher Scientific launched its Ion AmpliSeq HLA Panels v3 optimized for the Genexus Integrated Sequencer, offering improved Class I and Class II HLA coverage and faster turnaround times for transplant laboratories, helping to streamline donor‑recipient compatibility testing
• In October 2024, CareDx, Inc. introduced AlloSeq cfDNA v2, a cell‑free DNA assay that integrates HLA typing with transplant surveillance, enabling clinicians to monitor potential organ rejection and compatibility more effectively and offering enhanced post‑transplant follow‑up capabilities
• In November 2024, DiaSorin S.p.A. updated its xMAP‑based HLA typing panels, expanding Class II allele libraries and providing enhanced mid‑throughput HLA typing solutions tailored for small to mid‑sized transplant centers, improving accuracy and allele coverage
• In September 2024, Immucor unveiled its LIFECODES LifeScreen Deluxe, a high‑resolution antibody screening platform designed to improve the accuracy and speed of donor‑recipient matching in transplant diagnostics, advancing immunogenetic screening capabilities at transplant centers
• In August 2024, Thermo Fisher Scientific received U.S. FDA 510(k) clearance for its SeCore CDx HLA A Sequencing System, approved as a companion diagnostic for TECELRA (afamitresgene autoleucel), enhancing precision HLA typing applications linked to immunotherapies and transplant eligibility

SKU-17321